Trial Profile
A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Mar 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- Acronyms DoRIS
- 10 Mar 2023 Planned End Date changed from 1 Mar 2024 to 1 Mar 2027.
- 19 Jan 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2024.
- 06 Mar 2018 Status changed from recruiting to active, no longer recruiting.